Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 19/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11913127 | 0.87 | GPR119 (0.51) | GPR119CYP2C9CYP3A4KCNH2 | |
| SCHEMBL10151300 | 0.87 | CYP2C9 (0.58) | GPR119CYP2C9CYP3A4KCNH2 | |
| SCHEMBL1449874 | 0.84 | GPR119 (0.64) | GPR119CYP2C9CYP3A4KCNH2 | |
| SCHEMBL12744513 | 0.81 | GPR119 (0.46) | GPR119CYP2C9KCNH2 | |
| SCHEMBL11913138 | 0.78 | GPR119 (0.63) | GPR119CYP2C9KCNH2 | |
| SCHEMBL10151299 | 0.74 | CYP3A4 (0.55) | GPR119CYP2C9CYP3A4 | |
| SCHEMBL10137752 | 0.73 | CYP2C9 (0.63) | GPR119CYP2C9CYP3A4KCNH2 | |
| SCHEMBL12596422 | 0.72 | GPR119 (0.66) | GPR119CYP2C9CYP3A4KCNH2 | |
| SCHEMBL12596504 | 0.72 | GPR119 (0.54) | GPR119CYP2C9CYP3A4 | |
| SCHEMBL14927795 | 0.71 | GPR119 (0.51) | GPR119CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293690-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293690-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR6, GPR139 | GPR119 1/4885CYP2C9 730/4885CYP3A4 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.